The manufacturing process for cell therapies, which is costly and prone to error, is seeing a surge of innovation and investment. The Cell & Gene Live event at Vittoria Biotherapeutics co-founder and CEO, Dr. Nicholas Siciliano, and established executive in cell and gene therapy quality, Will Junker, highlighted the need for real-time analytics built into the system to improve turnaround time for production. While both Junker and Sicilliano believe that humans will remain integral to advanced therapies manufacturing, they also predict that as technology advances and manufacturing becomes more automated, job training and requirements will shift away from biology to programming and computer science. A fully automated, closed manufacturing system with built-in analytics is the holy grail.
Source
This post was brought to you by Wrk. Our bot looks for news related to automation and post daily.
